Manuel Vasquez
Adult Health · Victoria, TXNPI 1740386895
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Gilead at 38.2% of the total. Among adult health clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $36.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- Viiv Healthcare Company$2K
- Janssen Products, LP$594
- Merck$568
- Theratechnologies Inc.$354
- Johnson & Johnson$293
- plus $842 from 10 others
What the payments were for
- Speaking & faculty fees$581%
- Food & beverage$7,40597%
- Education$1432%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 55 | $2,906 |
| Viiv Healthcare Company | 65 | $2,049 |
| Janssen Products, LP | 6 | $594 |
| Merck | 22 | $568 |
| Theratechnologies Inc. | 12 | $354 |
| Johnson & Johnson | 15 | $293 |
| Napo Pharmaceuticals Inc | 13 | $261 |
| AbbVie | 10 | $192 |
| Novo Nordisk | 1 | $111 |
| Janssen Scientific Affairs, LLC | 1 | $107 |
| Teleflex LLC | 4 | $70 |
| EMD Serono, Inc. | 1 | $25 |
| Abbott | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| VBI Vaccine (delaware) Inc. | 1 | $17 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,606 in reported general payments places this provider in the 90th percentile of 933 adult health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 108 | $428,569 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 56 | $257,411 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 69 | $248,936 |
| JulucaDolutegravir/Rilpivirine | 41 | $142,216 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 34 | $132,274 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 28 | $110,025 |
| CompleraEmtricita/Rilpivirine/Tenof Df | 17 | $65,318 |
| TivicayDolutegravir Sodium | 22 | $46,168 |
| DovatoDolutegravir Sodium/Lamivudine | 15 | $41,532 |
| OzempicSemaglutide | 20 | $17,238 |
| JanuviaSitagliptin Phosphate | 12 | $5,514 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $4,559 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $4,188 |
| Darunavir | 12 | $3,490 |
| Nevirapine ErNevirapine | 14 | $2,457 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Stribild | $2,906 | $538,594136 claims |
| Viiv Healthcare CompanyJuluca, Triumeq, Tivicay, Dovato | $2,049 | $362,190112 claims |
| Janssen Products, LPSymtuza | $594 | $257,41156 claims |
| Johnson & JohnsonComplera | $293 | $65,31817 claims |
| Novo NordiskOzempic | $111 | $17,23820 claims |
| MerckJanuvia | $568 | $5,51412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 adult health providers in Texas.
Other adult health in Victoria
- Misty SheddAllen$863K
- Melodie YoungDallas$700K
- Cynthia BedellPlano$168K
- Elizabeth Wedberg SivamAustin$71K
- Mary SalazarSan Antonio$68K
- Eric KlappholzDallas$44K
- Christin TouchetKingwood$43K
- Yulia LyuboslavskyAustin$36K
- Meghan MurphyAustin$29K
- Sandra CareyGrapevine$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.